CNPY2 and Familial prostate cancer: Finally, to investigate whether CNPY2 inhibited MYLIP-mediated AR degradation in prostate cancer cells, AR protein levels were examined by immunoblotting of lysates from either CNPY2 or MYLIP knockdown LNCaP cells (Figure 2H).